DK0660717T3 - Aminosteroider til ophthalmisk anvendelse - Google Patents

Aminosteroider til ophthalmisk anvendelse

Info

Publication number
DK0660717T3
DK0660717T3 DK91910700T DK91910700T DK0660717T3 DK 0660717 T3 DK0660717 T3 DK 0660717T3 DK 91910700 T DK91910700 T DK 91910700T DK 91910700 T DK91910700 T DK 91910700T DK 0660717 T3 DK0660717 T3 DK 0660717T3
Authority
DK
Denmark
Prior art keywords
therapeutic agents
stabilizing
amounts
stabilized
cyclodextrin
Prior art date
Application number
DK91910700T
Other languages
Danish (da)
English (en)
Inventor
Santosh Kumar Chandrasekaran
John C Babcock
Lyle M Bowman
Jon R Polansky
Sheng-Wang Tsao
Erwin Chun-Chit Si
Original Assignee
Insite Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insite Vision Inc filed Critical Insite Vision Inc
Application granted granted Critical
Publication of DK0660717T3 publication Critical patent/DK0660717T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK91910700T 1990-06-12 1991-05-17 Aminosteroider til ophthalmisk anvendelse DK0660717T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/537,062 US5124154A (en) 1990-06-12 1990-06-12 Aminosteroids for ophthalmic use
PCT/US1991/003321 WO1991019482A1 (fr) 1990-06-12 1991-05-17 Aminosteroides utilises en ophtalmologie

Publications (1)

Publication Number Publication Date
DK0660717T3 true DK0660717T3 (da) 1998-12-21

Family

ID=24141030

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91910700T DK0660717T3 (da) 1990-06-12 1991-05-17 Aminosteroider til ophthalmisk anvendelse

Country Status (12)

Country Link
US (3) US5124154A (fr)
EP (1) EP0660717B1 (fr)
JP (1) JPH05507916A (fr)
AT (1) ATE163853T1 (fr)
AU (1) AU8090791A (fr)
CA (1) CA2085245A1 (fr)
DE (1) DE69129078T2 (fr)
DK (1) DK0660717T3 (fr)
ES (1) ES2116292T3 (fr)
NZ (1) NZ238240A (fr)
WO (1) WO1991019482A1 (fr)
ZA (1) ZA913908B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5340572A (en) * 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
FR2706896B1 (fr) * 1993-06-23 1996-04-12 Caillot Jean Luc
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
US5458883A (en) 1994-01-12 1995-10-17 Duke University Method of treating disorders of the eye
US5592949A (en) * 1994-06-29 1997-01-14 Moench; Thomas R. Device for acidic buffering and method for inactivation of pathogens
HUT76808A (en) * 1994-09-01 1997-11-28 Upjohn Co Cosolvent parenteral formulation of tirilazad
US5789169A (en) * 1994-11-03 1998-08-04 Regents Of The University Of California Methods for the diagnosis of glaucoma
US5606043A (en) 1994-11-03 1997-02-25 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5849879A (en) * 1994-11-03 1998-12-15 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5614515A (en) * 1994-11-17 1997-03-25 University Of Southern California Lazaroid-based compositions and method for preventing adhesion formation using the same
AU4612396A (en) * 1995-02-01 1997-08-11 Upjohn Company, The Use of tirilazad for caring for soft tissue edema
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US7084016B1 (en) * 1998-07-17 2006-08-01 Semiconductor Energy Laboratory Co., Ltd. Crystalline semiconductor thin film, method of fabricating the same, semiconductor device, and method of fabricating the same
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
WO2000012137A1 (fr) 1998-09-02 2000-03-09 Allergan Sales, Inc. Compositions contenant de la cyclodextrine et un agent conservateur
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6699492B2 (en) 1999-03-31 2004-03-02 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
US6685958B2 (en) 2001-04-25 2004-02-03 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
US6303157B1 (en) 2000-05-31 2001-10-16 Kava Pharmaceuticals, Inc. Extracts of kava-kava
US20040029831A1 (en) * 2000-05-31 2004-02-12 Kava Pharmaceuticals, Inc. Extracts of kava-kava
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
US6696426B2 (en) 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
US7709026B2 (en) * 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
US20030119000A1 (en) * 2001-11-05 2003-06-26 Jon Polansky Methods to screen and treat individuals with glaucoma or the propensity to develop glaucoma
KR100951606B1 (ko) * 2001-12-14 2010-04-09 알콘 인코포레이티드 안과 질환 및 질병의 치료를 위한 과산화물 디스뮤타제모방체
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
CN100453066C (zh) * 2002-12-04 2009-01-21 参天制药株式会社 利用结膜下储存库的药物释放系统
CA2522784C (fr) * 2003-04-01 2012-06-19 Hollis-Eden Pharmaceuticals, Inc. Antiandrogenes presentant une activite agoniste marginale, et methodes d'utilisation
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050137147A1 (en) * 2003-12-22 2005-06-23 Alcon, Inc. Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
DK1696958T3 (da) * 2003-12-22 2007-07-09 Alcon Inc Midler til behandling af glaukomatös retinopati og optiske neuropati
EP1706095B1 (fr) 2004-01-20 2008-12-24 Allergan, Inc. Compositions pour therapie localisee de l'oeil, de preference a base de triamcinolone acetonide et d'acide hyaluronique
US20060115870A1 (en) * 2004-03-30 2006-06-01 Alcon, Inc. High throughput assay for human Rho kinase activity
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
WO2005102345A1 (fr) * 2004-03-30 2005-11-03 Alcon, Inc. Utilisation d'inhibiteurs de kinase rho dans le traitement de deficits auditifs, d'acouphenes et dans l'amelioration de l'equilibre corporel
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
US7223737B1 (en) 2004-08-13 2007-05-29 Alcon, Inc. Method of treating dry eye disorders using glycosides
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
RU2007110731A (ru) * 2004-09-23 2008-10-27 Редди Юс Терапевтикс Новые соединения пиримидина, способ их получения и содержащие их композиции
WO2006110172A2 (fr) * 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals.Inc. Analogues de steroides, procedes de caracterisation et traitements
JP2008266142A (ja) * 2005-08-10 2008-11-06 Mitsubishi Pharma Corp 角膜障害の予防及び／又は治療剤
US20070224637A1 (en) * 2006-03-24 2007-09-27 Mcauliffe Joseph C Oxidative protection of lipid layer biosensors
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
KR101760139B1 (ko) * 2007-06-29 2017-07-31 클라렌슈 피티와이 리미티드 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
US8778999B2 (en) * 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
WO2013043387A1 (fr) 2011-09-22 2013-03-28 Bausch & Lomb Incorporated Compositions ophtalmiques en gel
CN107007580A (zh) * 2012-02-03 2017-08-04 意大发马克股份公司 用于治疗肌肉萎缩症的化合物
PL3049100T3 (pl) * 2013-09-25 2020-06-01 Trefoil Therapeutics, Llc Zmodyfikowane czynniki wzrostu fibroblastu-1 do leczenia zaburzeń ocznych
JP2018507252A (ja) 2015-01-26 2018-03-15 ボシュ・アンド・ロム・インコーポレイテッドＢａｕｓｃｈ ＆ Ｌｏｍｂ Ｉｎｃｏｒｐｏｒａｔｅｄ 眼用懸濁組成物
US10443049B2 (en) 2017-01-24 2019-10-15 Northwestern University Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)
US11090255B2 (en) 2018-12-04 2021-08-17 Momentive Performance Materials Inc. Use of polycarboxylic acid compounds for the treatment of fibrious amino acid based substrates, especially hair
US11097023B1 (en) 2020-07-02 2021-08-24 Par Pharmaceutical, Inc. Pre-filled syringe containing sugammadex

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3947573A (en) * 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
US4192827A (en) * 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4039662A (en) * 1975-12-04 1977-08-02 Alcon Laboratories, Inc. Ophthalmic solution
NZ186631A (en) * 1977-03-14 1980-05-27 Richter Gedeon Vegyeszet Androstane-17s-spiro-5'-(2'-oxo - oxazolidine) derivatives and pharmaceutical compositions
US4127674A (en) * 1977-03-21 1978-11-28 Allergan Pharmaceuticals, Inc. Method of treatment for glaucoma
US4136250A (en) * 1977-07-20 1979-01-23 Ciba-Geigy Corporation Polysiloxane hydrogels
JPS6056684B2 (ja) * 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
GB2013084B (en) * 1978-01-25 1982-07-28 Alcon Lab Inc Ophthalmic drug dosage
NZ190007A (en) * 1978-04-01 1980-09-12 Richter Gedeon Vegyeszet Steroid-spiro-oxazolidinone derivatives and pharmaceutical compositions
US4407792A (en) * 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4230724A (en) * 1979-07-16 1980-10-28 Allergan Pharmaceuticals, Inc. Method of treating vascularization of the eye with Flurbiprofen
SU997682A1 (ru) * 1979-11-02 1983-02-23 Московский научно-исследовательский институт глазных болезней им.Гельмгольца Антигипоксическое средство при глаукоме
CA1188616A (fr) * 1981-06-11 1985-06-11 Hoffmann-La Roche Limited Preparations pharmaceutiques
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4443432A (en) * 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
US4461904A (en) * 1981-11-20 1984-07-24 Alcon Laboratories, Inc. 2-(Trisubstituted phenylimino)-imidazolines
US4644007A (en) * 1981-11-20 1987-02-17 Alcon Laboratories, Inc. 3-chloro-4-(4,5-dihydro-1H-imidazo-2-yl)-amino-5-alkylbenzoic acids, esters, salts, compositions and methods
CA1201066A (fr) * 1981-11-20 1986-02-25 Alcon Laboratories, Inc. Solutions de n-¬3,5-dichloro-4-(2- imidazolidinylidene-amino)-phenyl|-acetamide pour diminuer la pression intra-oculaire
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
GR78151B (fr) * 1982-04-05 1984-09-26 Alcon Lab Inc
US4559343A (en) * 1982-09-07 1985-12-17 Alcon Laboratories, Inc. Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
WO1984004681A1 (fr) * 1983-05-25 1984-12-06 Alcon Lab Inc Solution ophtalmique
EP0145714A1 (fr) * 1983-05-25 1985-06-26 Alcon Laboratories, Inc. Gel ophtalmique
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
AU565354B2 (en) * 1983-11-14 1987-09-10 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4524063A (en) * 1983-12-22 1985-06-18 Allergan Pharmaceuticals, Inc. Ophthalmic compositions
US4717725A (en) * 1984-04-11 1988-01-05 Alcon Laboratories, Inc. Ophthalmic wound healing with aldose reductase inhibitors
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPS6170996A (ja) * 1984-09-13 1986-04-11 Nikken Kagaku Kk マルトシル−α−サイクロデキストリンの製造方法
JPS6192592A (ja) * 1984-10-12 1986-05-10 Norin Suisansyo Shokuhin Sogo Kenkyusho 分岐サイクロデキストリンの製造方法
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4617186A (en) * 1984-12-28 1986-10-14 Alcon Laboratories, Inc. Sustained release drug delivery system utilizing bioadhesive polymers
JPS61197602A (ja) * 1985-02-28 1986-09-01 Nikken Kagaku Kk 新規分岐サイクロデキストリンおよびその製造方法
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
IL78144A0 (en) * 1985-04-04 1986-07-31 Draco Ab Novel androstane-17beta-carboxylic acid esters
JPS61236802A (ja) * 1985-04-13 1986-10-22 Nikken Kagaku Kk 新規な分岐γ―サイクロデキストリンの製造方法
JPS61287902A (ja) * 1985-06-17 1986-12-18 Nikken Kagaku Kk 新規分岐β―サイクロデキストリンの製造方法
JPS623795A (ja) * 1985-06-28 1987-01-09 Tokuyama Soda Co Ltd 分枝状シクロデキストリンの製造方法
WO1987001706A2 (fr) * 1985-09-12 1987-03-26 The Upjohn Company Amino-steroides c20 a c26
US5099019A (en) * 1985-09-12 1992-03-24 Upjohn Company Amines useful in producing pharmaceutically active CNS compounds
AU600915B2 (en) * 1985-09-25 1990-08-30 Alcon Laboratories, Inc. Fast response tubeless vacuum aspiration collection cassette
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
JPS62106901A (ja) * 1985-11-05 1987-05-18 Nikken Kagaku Kk ジグルコシル−β−サイクロデキストリンおよびその製造方法
JPH0635481B2 (ja) * 1986-01-14 1994-05-11 日研化学株式会社 ジグルコシル−α−サイクロデキストリンおよびその製造方法
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物
JPS6327440A (ja) * 1986-07-18 1988-02-05 Sanraku Inc グルコシル化分岐シクロデキストリン含有組成物
JPS6336793A (ja) * 1986-07-31 1988-02-17 Nikken Kagaku Kk ジマルトシル―γ―サイクロデキストリンの製造方法
PT85891B (pt) * 1986-10-10 1990-07-31 Roussel Uclaf Processo para a preparacao de 9-alfa-hidroxi-esteroides e dos respectivos derivados 9(11)-deidro bem como de composicoes farmaceuticas que os contem
US4822819A (en) * 1986-11-07 1989-04-18 Alcon Laboratories, Inc. Use of trimoprostil and derivatives in glaucoma therapy
JPH0764884B2 (ja) * 1986-11-27 1995-07-12 株式会社トクヤマ シクロデキストリン組成物
US4737492A (en) * 1986-12-31 1988-04-12 Alcon Laboratories, Inc. Sparingly soluble salts of cefamandole, and ophthalmic compositions containing same
US4820737A (en) * 1987-02-17 1989-04-11 University Of Iowa Research Foundation Lacrimal secretion stimulant (lss)
NZ224288A (en) * 1987-04-22 1989-12-21 Merrell Dow Pharma 17b-(cyclopropylamino)androst-5-en-3b-ol and related compounds and methods using these for treatment of non-humans
CA1338012C (fr) * 1987-04-27 1996-01-30 John Michael Mccall Amines possedant des proprietes pharmaceutiques
US5120843A (en) * 1987-04-27 1992-06-09 Upjohn Pharmaceutically active amines
FR2621316B1 (fr) * 1987-10-02 1991-06-21 Nativelle Sa Ets Nouveaux esters d'acide androstane 17-carboxylique, procede pour leur preparation, et medicament les contenant
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
SE8802402D0 (sv) * 1988-06-28 1988-06-28 Pharmacia Ab Novel esters
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use

Also Published As

Publication number Publication date
US5124154A (en) 1992-06-23
JPH05507916A (ja) 1993-11-11
WO1991019482A1 (fr) 1991-12-26
US5538721A (en) 1996-07-23
ZA913908B (en) 1992-02-26
EP0660717B1 (fr) 1998-03-11
EP0660717A4 (fr) 1994-03-18
DE69129078T2 (de) 1998-11-12
CA2085245A1 (fr) 1991-12-13
EP0660717A1 (fr) 1995-07-05
ATE163853T1 (de) 1998-03-15
AU8090791A (en) 1992-01-07
DE69129078D1 (de) 1998-04-16
US5332582A (en) 1994-07-26
NZ238240A (en) 1993-08-26
ES2116292T3 (es) 1998-07-16

Similar Documents

Publication Publication Date Title
DK0660717T3 (da) Aminosteroider til ophthalmisk anvendelse
EP0579435B1 (fr) Complexation à l'amide de cyclodextrines
IE893201L (en) Method and compositions for solubilization and stabilization¹of polypeptides, especially proteins
ATE212351T1 (de) Androsten-derivate
HUP0102033A2 (hu) PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére
JO1250B1 (en) New pharmaceutical preparations
RU94028890A (ru) Композиции производных циклодекстрина, композиции, содержащие лекарство и производные циклодекстринов
EP0214647A3 (en) Inclusion complexes of 7-isopropoxy-isoflavone and cyclodextrins, process for their preparation and pharmaceutical preparations containing these complexes
ATE321532T1 (de) Pharmazeutische zubereitungen und verfahren zu deren lokalen verabreichung
MEP38008A (en) Drospirenone for hormone replacement therapy
HUP0102483A2 (hu) Androszt-5-én-3béta, 17béta-diolt tartalmazó gyógyszerkészítmények
DE69518767D1 (de) Ondasetronhaltige oral anzuwendende arzneimittel
JPH02706A (ja) 水性医薬製剤
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
FR2729296B1 (fr) Compositions pharmaceutiques comprenant une superoxyde dismutase
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
ATE356637T1 (de) Supramolekulare komplexe enthaltende arzneimittel
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
Fridriksdóttir et al. Formulation and testing of methazolamide cyclodextrin eye drop solutions
NO955085D0 (no) Androstansteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
ATE199641T1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ATE181324T1 (de) Im kardiovaskulären system aktive seco-d-steroide und diese enthaltende pharmazeutische zubereitungen
Ramos-Martínez et al. Use of cyclodextrins as excipients in pharmaceutical products: why not in extemporaneous preparations?
NO955084L (no) Estrensteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
HUP0201629A2 (hu) Eletriptánt és ciklodextrinszármazékot tartalmazó gyógyászati komplex, ezt tartalmazó gyógyszerkészítmény, eljárás az előállítására és alkalmazása